Back to search

Article

Combination of artesunate and ruxolitinib inhibits T-lymphoblastic leukemia/lymphoma proliferation via the Janus kinase/signal transducer and activator of transcription pathway

2025-09-25

Abstract excerpt

<title>Abstract</title> <p>BACKGROUND T-lymphoblastic leukemia/lymphoma is a highly aggressive malignancy, and its prognosis after relapse is poor, with a 5-year overall survival rate of 35%. Mutations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway are the second most common mutation type in T-lymphoblastic leukemia/lymphoma, and hyperactivation of this pathway can promote...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7050241a-f7a8-5d71-ac2c-bc4d68a68342
DOI
10.21203/rs.3.rs-7241143/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Combination of artesunate and ruxolitinib inhibits T-lymphoblastic leukemia/lymphoma proliferation via the Janus kinase/signal transducer and activator of transcription pathwayDOI 10.21203/rs.3.rs-7241143/v1
Select a neighboring publication to make it the new centre.